New Delhi: Alopecia or hair loss might be a doable facet impact of Ozempic-like GLP-1 receptor agonists, notably semaglutide and tirzepatide, analysis has discovered.
The findings, revealed in The British Medical Journal, present that GLP-1RA customers had been 37 per cent extra more likely to develop alopecia than SGLT-2 inhibitor customers — diabetes medicine which goal kidneys to take away further sugar from urine — whereas that they had a 68 per cent larger threat, in comparison with customers of DPP-4 inhibitors.
DPP4-inhibitors are one other class of medication which block the DPP-4 enzyme and stimulate insulin launch. All of the medicine are prescribed as anti-diabetes remedies.
Researchers, together with these from the US’ College of Pennsylvania, mentioned that though absolute threat is low, consciousness of the potential impact might assist inform shared remedy choices.
“Use of GLP-1 receptor agonists was related to an elevated threat of non-scarring alopecia (the place hair follicles stay intact, leaving the potential for regrowth) in adults with kind 2 diabetes,” the authors wrote.
Fast weight reduction is a well known set off of hair shedding and may also result in iron or zinc deficiencies, which disrupt the hair development cycle, they mentioned and added hormonal adjustments might also be related.
Nonetheless, additional research are wanted to make clear the underlying mechanisms, the staff mentioned.
Digital affected person information from the College of Pennsylvania Well being System (Penn Medication) was analysed to check charges of alopecia in adults with kind 2 diabetes who began utilizing GLP-1 receptor agonists or different varieties of diabetes medicine together with, SGLT-2 inhibitors and DPP-4 inhibitors.
Total, 12,004 sufferers utilizing GLP-1 receptor agonists had been in contrast with 15,221 utilizing SGLT-2 inhibitors and an extra 11,964 GLP-1 customers had been in contrast with 11,233 DPP-4 inhibitor customers between January 2019 and September 2024.
The researchers mentioned whereas the examine was a rigorous one, primarily based on prime quality information from a big consultant cohort, there are limitations.
For instance, a scarcity of scientific data restricted the staff’s capacity to evaluate particulars similar to severity, extent, period and reversibility of alopecia after stopping remedy. Nor can the authors rule out the chance that unmeasured elements might have influenced the outcomes.
“Our findings lengthen earlier anecdotal security indicators and supply extra systematic proof to tell scientific consciousness of this potential antagonistic impact,” they mentioned.
